Healthcare
Sunshine Biopharma, Inc.(SBFMW)
Live Price
Offline$0.0648
+8.54% today
1Y Change
-73.91%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +4.1%
- EPS Growth
- +80.3%
- Dividend Yield
- 0.0%
Coverage: 167 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sunshine Biopharma, Inc. (SBFMW) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.06 and down 73.9% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +4.1%, EPS growth of +80.3%, a dividend yield of 0.0%. What stands out right now is revenue +4.1%, EPS +80.3%, free cash flow +62.9% with operating margin -12.3% and ROIC -18.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines SBFMW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.1% vs +7.6% peer median
Operating Margin
Below sector median
-12.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.1% and EPS at +80.3%, with operating margin around -12.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -19.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Feb 25, 2026 | โ | -3.2% | -59.4% | -65.4% |
2025 Nov 13, 2025 | -46.1% | -10.8% | +0.3% | -12.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SBFMW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SBFMW Max Drawdown
-85.68%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SBFMW and SPY.
Company Overview
Sunshine Biopharma, Inc.
NASDAQ Capital Market
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
- Leadership
- Steve N. Slilaty
- IPO Date
- Feb 15, 2022
- Employees
- 52
- Street Address
- 6500 Trans-Canada Highway
- Mailing
- Pointe-Claire, QC, H9R 0A5
- Region
- Pointe-Claire, QC, CA
- Reporting Currency
- USD
- Investor Line
- 332 216 1147
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.6
- Price/Sales
- 0.1
- Price/Book
- 0.2
Growth
- Revenue
- +4.1%
- EPS
- +80.3%
- Free Cash Flow
- +62.9%
Profitability
- Gross Margin
- 33.5%
- Operating Margin
- -12.3%
- Net Margin
- -16.5%
- ROE
- -25.0%
- ROIC
- -18.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 4.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.